右旋甲狀腺素

右旋甲狀腺素
臨床資料
商品名（英語：Drug nomenclature）	Choloxin
其他名稱	D-3,5,3',5'-tetraiodothyronine
AHFS/Drugs.com	Multum消費者信息
ATC碼	C10AX01 (WHO) ;
法律規範狀態
法律規範	Discontinued;
識別資訊
	IUPAC命名法 (2R)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid; ;
CAS號	51-49-0
PubChem CID	8730;
DrugBank	DB00509;
ChemSpider	8402;
UNII	4W9K63FION;
ChEBI	CHEBI:30659;
ChEMBL	ChEMBL559;
CompTox Dashboard（英語：CompTox Chemicals Dashboard） (EPA)	DTXSID60199000 ;
ECHA InfoCard	100.000.094
化學資訊
化學式	C15H11I4NO4
摩爾質量	776.87 g·mol−1
3D模型（JSmol（英語：JSmol））	交互式圖像;
	SMILES O=C(O)[C@H](N)Cc2cc(I)c(Oc1cc(I)c(O)c(I)c1)c(I)c2;
	InChI InChI=1S/C15H11I4NO4/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23/h1-2,4-5,12,21H,3,20H2,(H,22,23)/t12-/m1/s1; Key:XUIIKFGFIJCVMT-GFCCVEGCSA-N;

右旋甲狀腺素，英文：Dextrothyroxine，商品名：Choloxin，是甲狀腺素的右旋異構體。^[1]起初該化合物被研發，以用於降膽固醇藥物^[2]，但由於其心臟副作用而被退出市場。該藥物會增加肝脂肪酶，從而提高三酸甘油酯的利用率並降低血清中脂蛋白（a）的水平。^[3]

參見

左旋甲狀腺素

參考文獻

^ Dextrothyroxine (Code C61719). NCI Thesaurus. National Cancer Institute. 2011-11-14 [2020-01-28]. （原始內容存檔於2023-05-22）.
^ Bantle JP, Hunninghake DB, Frantz ID, Kuba K, Mariash CN, Oppenheimer JH. Comparison of effectiveness of thyrotropin-suppressive doses of D- and L-thyroxine in treatment of hypercholesterolemia. The American Journal of Medicine. September 1984, 77 (3): 475–81. PMID 6475988. doi:10.1016/0002-9343(84)90107-4.
^ Bommer C, Werle E, Walter-Sack I, Keller C, Gehlen F, Wanner C, et al. D-thyroxine reduces lipoprotein(a) serum concentration in dialysis patients. Journal of the American Society of Nephrology. January 1998, 9 (1): 90–6. PMID 9440092.

[1] Dextrothyroxine (Code C61719). NCI Thesaurus. National Cancer Institute. 2011-11-14 [2020-01-28]. （原始內容存檔於2023-05-22）.

[2] Bantle JP, Hunninghake DB, Frantz ID, Kuba K, Mariash CN, Oppenheimer JH. Comparison of effectiveness of thyrotropin-suppressive doses of D- and L-thyroxine in treatment of hypercholesterolemia. The American Journal of Medicine. September 1984, 77 (3): 475–81. PMID 6475988. doi:10.1016/0002-9343(84)90107-4.

[3] Bommer C, Werle E, Walter-Sack I, Keller C, Gehlen F, Wanner C, et al. D-thyroxine reduces lipoprotein(a) serum concentration in dialysis patients. Journal of the American Society of Nephrology. January 1998, 9 (1): 90–6. PMID 9440092.

[1]

[2]

[3]